Ab 20004
Alternative Names: Ab-20004Latest Information Update: 30 Sep 2021
At a glance
- Originator Nanjing IASO Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 26 Sep 2021 Preclinical trials in Acute myeloid leukaemia in China (Parenteral) (Nanjing IASO Biotherapeutics pipeline, September 2021)